Search | Clinical Trials Finder

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Pentamidine isethionate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1991
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: HIV Infections, Hepatic Impairment
Interventions: efavirenz containing antiretroviral regimen; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 3
States / cities: Baltimore, Maryland • San Antonio, Texas • Richmond, Virginia

Conditions: HIV Infections
Interventions: Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 22
States / cities: Birmingham, Alabama • San Francisco, California • Denver, Colorado + 12 more

Conditions: HIV Infections
Interventions: Zidovudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: Human Immunodeficiency Virus, Substance Abuse, Intravenous
Interventions: BRIDGE; Other
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 616 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections, Sexually Transmitted Diseases
Interventions: Video-based HIV/STD prevention intervention; Device
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: Not listed
Enrollment: 45,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2009
U.S. locations: 4
States / cities: Long Beach, California • San Francisco, California • Denver, Colorado + 1 more

Conditions: HIV Infections, Sexually Transmitted Diseases
Interventions: Brief Motivational Intervention, Brief Informational Intervention, Intensive Informational Intervention, Intensive Info-Motivation-Behavioral Skills Intervention; Behavioral
Lead sponsor: The Miriam Hospital; Other
Eligibility: 18 Years and older
Enrollment: 1,554 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: HIV Infections
Interventions: Enfuvirtide, Raltegravir, Darunavir, Tipranavir, Etravirine, Maraviroc; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years and older
Enrollment: 517 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 61
States / cities: Birmingham, Alabama • Long Beach, California • Los Angeles, California + 34 more

Conditions: HIV
Interventions: Holistic Health Recovery Program for HIV+; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: HIV Infections, Acquired Immunodeficiency Syndrome
Interventions: Structured Ecosystems Therapy (SET), Individually tailored intervention; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV Prevention, Opioid-Related Disorders
Interventions: Pre-release Initiation of MMT, Post Release Initiation of MMT., Standard of Care Plus; Behavioral
Lead sponsor: The Miriam Hospital; Other
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: HIV Infections
Interventions: Lamivudine, Zidovudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 3 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Morristown, New Jersey

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 53
States / cities: Birmingham, Alabama • Harbor City, California • Los Angeles, California + 30 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Sitamaquine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1993
U.S. locations: 2
States / cities: Indianapolis, Indiana • Baltimore, Maryland

Conditions: HIV/AIDS, HIV-1-infection, Osteopenia
Interventions: Dolutegravir (DTG) 50MG/lamivudine (3TC) 300MG FIXED DOSE COMBINATION (FDC), Current tenofovir alafenamide (TAF)-containing ART regimen; Drug
Lead sponsor: Philip Grant; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 10
States / cities: Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 7 more

Conditions: HIV Infections
Interventions: Low dose Kaletra tablets; Drug
Lead sponsor: Phoenix Children's Hospital; Other
Eligibility: 3 Years to 18 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: HIV Infections
Interventions: VRC-HIVDNA016-00-VP, VRC-HIVADV014-00-VP, VRC-HIVDNA016-00-VP placebo, VRC-HIVADV014-00-VP placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 480 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 5
States / cities: Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 2 more

Conditions: Prevention of HIV Infection, STI Prevention
Interventions: Juntas Adelante: A Peer coaching Intervention to Promote Chemoprophylaxis for HIV Prevention among Latina Transgender Women in the Washington DC Metropolitan Area.; Behavioral
Lead sponsor: George Washington University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: HIV Infections
Interventions: Lamivudine/Zidovudine, Nelfinavir mesylate, Saquinavir, Delavirdine mesylate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 16
States / cities: Menlo Park, California • Stanford, California • Denver, Colorado + 12 more

Conditions: HIV Infections
Interventions: MN rgp120/HIV-1, TBC-3B Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1999
U.S. locations: 4
States / cities: Baltimore, Maryland • St Louis, Missouri • Nashville, Tennessee + 1 more

Conditions: HIV Infections
Interventions: Probenecid, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1989
U.S. locations: 2
States / cities: Sacramento, California • Baltimore, Maryland

Conditions: HIV Infection
Interventions: MEMS cap; Device
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 19 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Human Immunodeficiency Virus
Interventions: Silicone Elastomer Vaginal Ring, Female Condom; Combination Product · Device
Lead sponsor: International Partnership for Microbicides, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Human Immunodeficiency Virus Positive or Negative
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Aerosols in the Treatment of Pneumocystis Pneumonia: A Pilot Study Quantitating the Deposition of Aerosolized Pentamidine as Delivered in ACTG 040 and Comparing Its Toxicity With Parenteral Pentamidine Therapy

Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic Impairment

A Multicenter Phase II Double-Blind Exploratory Study to Evaluate Differences Among Various Zidovudine/Didanosine Regimens on Quantitative Measures of Viral Burden in Relatively Early HIV-1 Infection

The Safety and Effectiveness of Retrovir in HIV-Infected Patients Who Have Problems Related to the Nervous System

BRIDGE: Improving HIV Service Delivery for People Who Inject Drugs

Video-based Intervention Study to Prevent HIV/Sexually Transmitted Diseases (STDs) Among STD Clinic Patients

HIV Prevention Program for Patients Receiving Care at a Sexually Transmitted Diseases Clinic

Optimizing Treatment for Treatment-Experienced, HIV-Infected People

PLUS PINK: HHRP+ Adaptation for Women With HIV Under Community Supervision

Effectiveness of Structured Ecosystems Therapy for Reducing HIV Risk Behaviors and Improving Treatment Adherence in HIV Infected Men Released From Prison

Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1

3TC (Lamivudine; GR109714X) Open-Label Program

A Study to Evaluate the Impact of Stopping Treatment for the Prevention of Pneumonia in HIV-Positive Patients Receiving Anti-HIV Drugs Who Have Increased CD4 Cell Counts

Escalating Multiple-Dose Safety and Tolerance of WR 6026 Hydrochloride in HIV-Infected Subjects

Effect of Reducing Nucleotide Exposure on Bone Health (ReNew)

Comparison of Liquid Kaletra and Low Dose Kaletra Tablets

HVTN Protocol 204 - A Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed by a Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine Boost, VRCHIVADV014-00-VP, in HIV-1 Uninfected Adult Participants

Juntas Adelante: A Peer-Coaching Intervention to Promote Chemoprophylaxis for HIV Prevention Among Latina Transgender Women in the Washington DC Metropolitan Area.

A Comparison of Nelfinavir Plus Saquinavir Plus Delavirdine or 3TC/ZDV Versus Nelfinavir Plus 3TC/ZDV in HIV-Infected Patients

A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of the Therion Recombinant Vaccinia-HIV-1 IIIB ENV/GAG/POL Vaccine (TCB-3B) and MN RGP 120/HIV-1 In Alum.

Safety and Tolerance of Zidovudine With Probenecid and the Effect of Probenecid on Zidovudine Pharmacokinetics Over Four Weeks

Characterization of the Adherence Threshold for HIV Suppression of a Kaletra-based Regimen

A Trial to Assess the Functionality of Female Condom With a Silicone Elastomer Vaginal Ring

Effects of Endocrine Health on Mental Performance of Men and Women Using Drugs